key: cord-1030731-d6xb5q0o authors: Vono, Maria; Huttner, Angela; Lemeille, Sylvain; Martinez-Murillo, Paola; Meyer, Benjamin; Baggio, Stephanie; Sharma, Shilpee; Thiriard, Anais; Marchant, Arnaud; Godeke, Gert-Jan; Reusken, Chantal; Alvarez, Catia; Perez-Rodriguez, Francisco; Eckerle, Isabella; Kaiser, Laurent; Loevy, Natasha; Eberhardt, Christiane S.; Blanchard-Rohner, Geraldine; Siegrist, Claire-Anne; Didierlaurent, Arnaud M. title: Robust innate responses to SARS-CoV-2 in children resolve faster than in adults without compromising adaptive immunity date: 2021-09-15 journal: Cell Rep DOI: 10.1016/j.celrep.2021.109773 sha: 818d3c82d3eab58fc5977c9892ce993bdbcabec3 doc_id: 1030731 cord_uid: d6xb5q0o SARS-CoV-2 infection in children is less severe than in adults. We perform a longitudinal analysis of the early innate responses in children and adults with mild infection within household clusters. Children display fewer symptoms than adults despite similar initial viral load and mount a robust anti-viral immune signature typical of SARS-CoV-2 infection and characterized by early interferon gene responses, increases in cytokines such as CXCL10 and GM-CSF, and changes in blood cell numbers. When compared to adults, the antiviral response resolves faster (within a week of symptoms); monocytes and dendritic cells are more transiently activated; and genes associated with B-cell activation appear earlier in children. Nonetheless, these differences do not have major effects on the quality of SARS-CoV-2 specific antibody responses. Our findings reveal that better early control of inflammation as observed in children may be key for rapidly controlling infection and limiting disease course. Clinical symptoms of SARS-CoV-2 infection are highly variable among individuals; it is not 59 yet clear what determines this variability. A consistent finding is the effect of age on disease 60 severity. The need for hospitalization due to severe disease and death is relatively rare in early innate events after infection in children is challenging to obtain and thus lacking. 95 Here we report a detailed profiling of the immune response to SARS-CoV-2 in household 96 clusters, from the onset of infection, including initial inflammatory antiviral responses, to its 97 resolution in the two following months and the generation of SARS-CoV-2 specific adaptive 98 immunity. Responses in children and adult household members were compared in the context 99 of mild COVID-19, the most common clinical presentation, and in the absence of any 100 treatment. We found that children do indeed mount early, robust innate responses, but these 101 resolve more rapidly than in adults. The rapid resolution does not, however, compromise the 102 induction or quality of SARS-CoV-2-specific adaptive immunity, which is comparable to that 103 seen in adults. negative and asymptomatic and thus served as negative controls followed for 2 weeks. The 118 sixteen infected children were distributed in ten household clusters (C1 to C10) holding 119 twelve infected adults, allowing paired comparisons between adults and children within the 120 same cluster ( Figure S2A and B). Participants were mainly from a Caucasian origin and 121 comorbidities were reported only in few infected adults (Table S1 ). All SARS-CoV-2 infections were mild. Fewer symptoms of shorter duration were reported by 123 children as compared to adults either in their respective households or in other households 124 ( Figure 1C -D and S2 for individual data). Among adults, some symptoms persisted for several 125 weeks (anosmia, cough, fatigue). Three children were totally asymptomatic and, there was no 126 difference in all immunological and virological read-outs presented in this study between 127 those three asymptomatic children when compared to the symptomatic children. Those with 128 the symptoms of longest duration were older, aged 14 and 16 years ( Figure S2A ). At the time of diagnosis, viral load in nasopharyngeal swabs (NPS) appeared similar among 130 infected children and adults ( Figure 1E ), in line with other reports (Baggio et al., 2020; 131 Colson et al., 2020; Heald-Sargent et al., 2020). Similar broad ranges of viral load (10 2 to 10 9 132 genome copies/ml) were also detected between inclusion and 18 DPOS ( Figure 1F ). There 133 were no significant differences in viral clearance between adults and children despite major Figure S4 ). To better compare gene expression between adults and children, we assessed differential gene 3A-D). Significantly up or down regulated genes (P value <0.05 and abs(log2FC)>1.5) were 159 then analysed using BTMs. During the first five DPOS there was significant up-regulation of The activation marker CD86 on monocyte and DC subsets was significantly upregulated Overall, all children could mount an innate-immune response to SARS-CoV-2 as robust as in 230 adults, but the response resolved faster in children. Lower pre-existing humoral immunity to common-cold HCoVs in children 232 At the first visit, no IgG antibodies to the S1 domain of the SARS-CoV-2 spike antigen were 233 detected in our study population ( Figure 7A ). In contrast, IgGs specific to S1 of the other four 234 HCoVs were detected at the first visit, indicating previous exposure. S1 HCoV-specific IgGs Interestingly, they also highlighted higher activation of neutrophils in children which were 307 also strongly reduced in numbers in our cohort, highlighting a potential role of neutrophils in 308 the early control of infection. 309 We had presumed that inflammatory responses to SARS-CoV-2 would drive inflammatory Our study had several limitations, chief among them its observational design and its relatively 357 small size. All patients had mild COVID and therefore our data cannot be extrapolated to 358 more severe disease. Differences in symptom profiles between adults and children meant that 359 we could not match their profiles for direct comparisons. In conclusion, our data suggest that the fewer symptoms of shorter duration in children may 361 reflect their more rapid resolution of innate responses to SARS-CoV-2. THP-1 cell/ml were added to each well and incubated 16 hours at 37°C, 5% C02. Finally, 675 cells were centrifuged (125 g, 10 min) and 100 µl of the supernatant was substituted by 100 µl 676 of 1X CellFIX (BD #340181). The acquisition was done by using a LSR-Fortessa (BD). Results were expressed as phagocytic score: FITC + frequency X FITC + mean *10 -4 . Assays 678 performed without IgG and with a pool of IgG obtained from healthy blood donors before the 679 COVID-19 pandemic were used as negative controls. Neutralization assay (sVNT) 681 Neutralization capacity of serum samples was assessed using a commercially available A robust, high-throughput assay to determine the phagocytic 738 activity of clinical antibody samples Human coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 in children Seasonal human coronavirus antibodies 743 are boosted upon SARS-CoV-2 infection but not associated with protection The association of viral load and disease severity in children 746 with COVID-19 SARS-CoV-2 viral load in the upper respiratory tract of children 749 and adults with early acute COVID-19 Humoral signatures of protective and pathological SARS-CoV-2 infection 752 in children Why is COVID-19 so mild in children? Enzyme 2 in Children and Adults Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in 758 Children and Adolescents: A Systematic Review Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production Children account for a small proportion of diagnoses 764 of SARS-CoV-2 infection and do not exhibit greater viral loads than adults The Immunology of Multisystem Inflammatory Syndrome in Children 768 with COVID-19 Detection of 2019 novel coronavirus (2019-nCoV) by real-771 time RT-PCR Virological and immunological features of SARS-CoV-2-774 infected children who develop neutralizing antibodies Sustained IFN-I Expression during Established Persistent Viral Infection: A "Bad Seed" for 777 Protective Immunity Influence of Age and Other Factors on Cytokine 779 Expression Profiles in Healthy Children-A Systematic Review Trained immunity, tolerance, priming and 782 differentiation: distinct immunological processes STAR: ultrafast universal RNA-seq aligner Age-related changes in human blood 787 lymphocyte subpopulations SARS-CoV-2 infections in children and young people A 791 high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce 792 complement activation Young infants exhibit robust functional antibody 795 responses and restrained IFN-γ production to SARS-CoV-2 Immunological assessment of pediatric multisystem 798 inflammatory syndrome related to COVID-19 Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) 801 Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19) Immune profiles provide insights into respiratory 805 syncytial virus disease severity in young children Laboratory abnormalities in children with novel 807 coronavirus disease 2019 The potential danger of suboptimal antibody responses in COVID-19 Anti-severe acute respiratory syndrome coronavirus spike antibodies 812 trigger infection of human immune cells via a pH-and cysteine protease-independent FcgammaR 813 pathway Profiling of humoral immune 816 responses to influenza viruses by using protein microarray Molecular signatures of antibody responses derived 819 from a systems biology study of five human vaccines featureCounts: an efficient general purpose program for 821 assigning sequence reads to genomic features SARS-CoV-2 Infection in Children Longitudinal analyses reveal immunological misfiring in severe COVID-19. 826 Modelling estimates of age-specific influenza-related hospitalisation and mortality in the United 829 Kingdom Validation and clinical evaluation of a SARS-CoV-2 832 surrogate virus neutralisation test (sVNT) Will children reveal their secret? The coronavirus 834 dilemma Immune response in children with COVID-19 is characterized by 837 lower levels of T-cell activation than infected adults Distinct inflammatory profiles distinguish COVID-840 19 from influenza with limited contributions from cytokine storm COVID-19 in children: current evidence and key questions Single-cell meta-analysis of SARS-CoV-2 entry genes 845 across tissues and demographics Innate cell profiles during the acute and convalescent 848 phase of SARS-CoV-2 infection in children Preexisting and de novo humoral immunity to SARS-CoV-2 in humans Immunopathogenesis of coronavirus infections: implications 853 for SARS Immune responses to SARS-CoV-2 infection in 856 hospitalized pediatric and adult patients Natural mucosal barriers and COVID-19 in children Specific serology for emerging human 861 coronaviruses by protein microarray Hyperinflammatory shock in children during COVID-19 pandemic edgeR: a Bioconductor package for 865 differential expression analysis of digital gene expression data Airways Expression of SARS-CoV-2 Receptor, ACE2, and TMPRSS2 Is Lower in 868 Children Than Adults and Increases with Smoking and COPD Age-dependent differences in pulmonary host Age-determined expression of priming 874 protease TMPRSS2 and localization of SARS-CoV-2 in lung epithelium Systems serology detects functionally distinct 877 coronavirus antibody features in children and elderly Global, regional, and national disease burden estimates of 880 acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a 881 systematic review and modelling study Seroprevalence of anti-SARS-CoV-2 IgG antibodies in SEROCoV-POP): a population-based study Plasmacytoid dendritic cells during infancy are inversely associated with childhood respiratory tract 887 infections and wheezing Dendritic 889 cell subsets in childhood and in children with cancer: relation to age and disease prognosis Effects of Ageing on the Immune System: Infants 892 to Elderly Accurate serology for SARS-CoV-2 and common human 895 coronaviruses using a multiplex approach An outbreak of severe Kawasaki CoV-2 epidemic: an observational cohort study Susceptibility to SARS-CoV-2 Infection Among 901 Children and Adolescents Compared With Adults: A Systematic Review and Meta-analysis Dysregulation of the immune response affects 904 the outcome of critical COVID-19 patients Distinct antibody responses to SARS-CoV-2 in children and adults 907 across the COVID-19 clinical spectrum Differences in Immunological Responses to SARS-CoV-2 Clinical 911 and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease Antibody-dependent infection of human macrophages by severe acute respiratory 915 syndrome coronavirus Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 918 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses Inborn errors of type I IFN immunity in patients with life-threatening 921 COVID-19 SARS-CoV-2-923 induced immune activation and death of monocyte-derived human macrophages and dendritic cells Coronavirus Infections in Children Including COVID-19: An 926 Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in 927 Children